$AVNS

Galovan Scott Michael sold (to issuer) $5.8M of AVNS

Galovan Scott Michael (SVP, Chief Financial Officer) sold (to issuer) 231,717 shares of AVANOS MEDICAL, INC. (AVNS) at $25.00 ($5.79M total) across 2 trades on 2026-07-27.

Original reporting
SEC EDGAR · Galovan Scott Michael
Published Jul 28, 2026, 9:39 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AVNS
Neutral
high confidence
Mentioned
$AVNS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVNSNeutralLow
01

Why it matters

The newest fact is the CFO’s sale to the issuer at a fixed $25.00/share price and the resulting 0-share direct holdings; it may influence sentiment but does not introduce new business fundamentals.

02

Market read

Traders may monitor for sentiment effects from insider selling, but the disclosure lacks fundamental catalysts.

03

What to watch

The filing does not state intent beyond the transaction code, and it provides no linkage to earnings, guidance, or operational changes.

Relevance 6/10Novelty 5/10Timing: Filed 2026-07-28 for a 2026-07-27 insider sale to the issuer.

Background

The article is an SEC Form 4 insider transaction disclosure for AVANOS MEDICAL, Inc. (AVNS).

Company-level read

Ticker impact

$AVNSNeutralHigh confidence
Context

AVANOS MEDICAL CFO Galovan Scott Michael sold 231,717 shares to the issuer at $25.00/share, leaving 0 shares after the transaction.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider transaction with a specific sale price and post-transaction holdings of 0 shares, but it provides no new operating or guidance information.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the transaction is 'sale to issuer' (often tied to buyback mechanics), it may reflect planned liquidity rather than bearish conviction.

Key entities

  • AVANOS MEDICAL, INC.

    Company whose CFO insider transaction was disclosed on Form 4.

  • Galovan Scott Michael

    SVP and Chief Financial Officer who sold shares to the issuer.

Related articles

$AVNSLow

AVANOS MEDICAL, INC. (AVNS): Completion of Acquisition or Disposition of Assets

AVANOS MEDICAL, INC. (AVNS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 4 avnsform8k_07272026xex101.htm EX-10.1 Document Execution Version CREDIT AGREEMENT dated as of July 27, 2026 among A-AV MERGERSUB, INC., as the Initial Borrower, AVANOS MEDICAL, INC., as the Borrower Representative, A-AV ACQUIRECO, INC., as a Borrower, A-AV INTERMEDIATEC